These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 29555610)

  • 21. Prolonged administration of temozolomide in adult patients with anaplastic glioma.
    Freyschlag CF; Smolczyk DR; Janzen E; Schmieder K; Thomé C; Lohr F; Wenz F; Weiss C; Tuettenberg J; Seiz M
    Anticancer Res; 2011 Nov; 31(11):3873-7. PubMed ID: 22110212
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Feasibility of preirradiation temozolomide in cases of high-grade gliomas: Our experience and review of literature.
    Arora S; Rathi AK; Singh K; Ansari FA
    J Cancer Res Ther; 2023; 19(2):221-227. PubMed ID: 37006062
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.
    Perry JR; Bélanger K; Mason WP; Fulton D; Kavan P; Easaw J; Shields C; Kirby S; Macdonald DR; Eisenstat DD; Thiessen B; Forsyth P; Pouliot JF
    J Clin Oncol; 2010 Apr; 28(12):2051-7. PubMed ID: 20308655
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Encouraging experience of concomitant Temozolomide with radiotherapy followed by adjuvant Temozolomide in newly diagnosed glioblastoma multiforme: single institution experience.
    Jalali R; Basu A; Gupta T; Munshi A; Menon H; Sarin R; Goel A
    Br J Neurosurg; 2007 Dec; 21(6):583-7. PubMed ID: 18071985
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme.
    Chen C; Damek D; Gaspar LE; Waziri A; Lillehei K; Kleinschmidt-DeMasters BK; Robischon M; Stuhr K; Rusthoven KE; Kavanagh BD
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1066-74. PubMed ID: 20932651
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Temozolomide for malignant primary spinal cord glioma: an experience of six cases and a literature review.
    Kim WH; Yoon SH; Kim CY; Kim KJ; Lee MM; Choe G; Kim IA; Kim JH; Kim YJ; Kim HJ
    J Neurooncol; 2011 Jan; 101(2):247-54. PubMed ID: 20526650
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase II trial of arsenic trioxide and temozolomide in combination with radiation therapy for patients with malignant gliomas.
    Kumthekar P; Grimm S; Chandler J; Mehta M; Marymont M; Levy R; Muro K; Helenowski I; McCarthy K; Fountas L; Raizer J
    J Neurooncol; 2017 Jul; 133(3):589-594. PubMed ID: 28510787
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Temozolomide for the treatment of recurrent supratentorial glioma: results of a compassionate use program in Belgium.
    Everaert E; Neyns B; Joosens E; Strauven T; Branle F; Menten J
    J Neurooncol; 2004 Oct; 70(1):37-48. PubMed ID: 15527106
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG.
    Blumenthal DT; Gorlia T; Gilbert MR; Kim MM; Burt Nabors L; Mason WP; Hegi ME; Zhang P; Golfinopoulos V; Perry JR; Hyun Nam D; Erridge SC; Corn BW; Mirimanoff RO; Brown PD; Baumert BG; Mehta MP; van den Bent MJ; Reardon DA; Weller M; Stupp R
    Neuro Oncol; 2017 Aug; 19(8):1119-1126. PubMed ID: 28371907
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of carbon ion radiotherapy to photon radiation alone or in combination with temozolomide in patients with high-grade gliomas: explorative hypothesis-generating retrospective analysis.
    Combs SE; Bruckner T; Mizoe JE; Kamada T; Tsujii H; Kieser M; Debus J
    Radiother Oncol; 2013 Jul; 108(1):132-5. PubMed ID: 23932193
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A multicenter prospective observational study of the conformity of temozolomide prescriptions in France.
    Tilleul P; Brignone M; Hassani Y; Labrande C; Pedeboscq S; Gensollen S; Lahille B; Exinger D; Bertholle V; Billard M; Charlety D; Prebay D; Pinguet F; Taillibert S; Cartalat S; Chinot O; Borget I;
    Pharmacoepidemiol Drug Saf; 2012 Aug; 21(8):828-34. PubMed ID: 22419509
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.
    Ishikawa E; Muragaki Y; Yamamoto T; Maruyama T; Tsuboi K; Ikuta S; Hashimoto K; Uemae Y; Ishihara T; Matsuda M; Matsutani M; Karasawa K; Nakazato Y; Abe T; Ohno T; Matsumura A
    J Neurosurg; 2014 Sep; 121(3):543-53. PubMed ID: 24995786
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial.
    Chang SM; Prados MD; Yung WK; Fine H; Junck L; Greenberg H; Robins HI; Mehta M; Fink KL; Jaeckle KA; Kuhn J; Hess K; Schold C
    Cancer; 2004 Apr; 100(8):1712-6. PubMed ID: 15073861
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas.
    Schiff D; Desjardins A; Cloughesy T; Mikkelsen T; Glantz M; Chamberlain MC; Reardon DA; Wen PY
    Cancer; 2016 Feb; 122(4):582-7. PubMed ID: 26588662
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Temozolomide: therapeutic limitations in the treatment of adult high-grade gliomas.
    Chamberlain MC
    Expert Rev Neurother; 2010 Oct; 10(10):1537-44. PubMed ID: 20925470
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Salvage temozolomide for prior temozolomide responders.
    Franceschi E; Omuro AM; Lassman AB; Demopoulos A; Nolan C; Abrey LE
    Cancer; 2005 Dec; 104(11):2473-6. PubMed ID: 16270316
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma.
    Gramatzki D; Kickingereder P; Hentschel B; Felsberg J; Herrlinger U; Schackert G; Tonn JC; Westphal M; Sabel M; Schlegel U; Wick W; Pietsch T; Reifenberger G; Loeffler M; Bendszus M; Weller M
    Neurology; 2017 Apr; 88(15):1422-1430. PubMed ID: 28298550
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factors predicting temozolomide induced clinically significant acute hematologic toxicity in patients with high-grade gliomas: a clinical audit.
    Gupta T; Mohanty S; Moiyadi A; Jalali R
    Clin Neurol Neurosurg; 2013 Sep; 115(9):1814-9. PubMed ID: 23764039
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic factors in glioblastoma patients managed with radiotherapy combined with temozolomide.
    Peponi E; Tourkantonis I; Tasiou I; Pavlidis N; Pentheroudakis G; Tsekeris P
    J BUON; 2014; 19(3):718-23. PubMed ID: 25261658
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dose-intensity temozolomide after concurrent chemoradiotherapy in operated high-grade gliomas.
    Dall'oglio S; D'Amico A; Pioli F; Gabbani M; Pasini F; Passarin MG; Talacchi A; Turazzi S; Maluta S
    J Neurooncol; 2008 Dec; 90(3):315-9. PubMed ID: 18688571
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.